Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of IBI362 9 mg in Chinese Adults With Obesity
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study evaluating the efficacy and safety of IBI362 9 mg in obese subjects. Subjects will be randomly assigned to IBI362 9 mg and placebo groups. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 2-week screening period, a 60-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.
Official title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of IBI362 9 mg in Chinese Participants With Obesity (GLORY-2)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
462
Start Date
2023-12-27
Completion Date
2025-09-19
Last Updated
2024-08-27
Healthy Volunteers
No
Conditions
Interventions
IBI362
Once-weekly injections of gradually increased doses of IBI362
Placebo
Once-weekly injections of volume-matched placebo
Locations (1)
Peking University People's Hospital
Beijing, Beijing Municipality, China